Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.

NCT05937906 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Phase I - Mirdametinib - Level 1
DRUG: Phase II - Mirdametinib
DRUG: Phase I - Mirdametinib - Level 2
DRUG: Phase I - Mirdametinib - Level 3
DRUG: Phase I - Mirdametinib - Level 4

Sponsor

Centre Georges Francois Leclerc